

Patents

We have more than 60 patent lawyers, technical specialists, and patent agents spanning our offices who have industry training and/or advanced degrees in life sciences and engineering, as well as experience as former patent office examiners well versed in the intricacies of the US Patent Office.

We work interactively with our clients to build and manage patent portfolios aligned with the client's business goals, whether it be to develop a patent portfolio for a pre-clinical product of an early-stage company, a blockbuster biologic for a major pharmaceutical company, a medical device for a multinational corporation, or computer hardware for a consumer product company. We have extensive domestic and international patent prosecution experience and are successful at developing strategic plans for our clients. We draw on our experience in patent litigation, technology licensing and transfer, corporate financing, and business representation to assist our clients in shaping a patent portfolio that best serves their strategic business interests.

We work with clients' patent committees, R&D and product development groups, research teams, engineers, and scientists to identify patentable subject matter and to devise patent prosecution strategies for maximizing global patent protection.

In addition to patent prosecution, we assist our clients with due diligence evaluations, patentability opinions, validity opinions, non-infringement opinions, and inventorship analyses and disputes. We partner with our clients to achieve their business objectives through acquisitions, joint ventures, collaborations, and public offerings.

Life Sciences

McCarter's life sciences intellectual property group has more than 25 PhD scientists with degrees in fields such as, molecular biology, cell biology, immunology, biochemistry, microbiology, virology, organic chemistry, and inorganic chemistry, and an MD. The group includes members with years of pharmaceutical industry experience, including both scientific and legal positions.

The scope and depth of our knowledge and training allows us to work as a team with our life sciences clients in all facets of intellectual property development, maintenance, and enforcement. We are experienced and innovative when it comes to the development and implementation of strategies for protecting our clients' technologies.

Our firm clients include some of the biggest names in the biotechnology, pharmaceutical, university and life sciences fields for whom we are building and managing complex, patent portfolios protecting blockbuster biotech and small molecule drugs and developing global strategic plans.

Examples of areas in which members of the McCarter life sciences IP group have prosecuted patent applications include biomarkers, gene therapy, protein formulations, diagnostic assays, crystallography, RNA interference, biofuels, genetic engineering, small molecule pharmaceuticals, medical devices, polymer chemistry, formulations, and plant biotechnology. We also have extensive experience prosecuting antibody patents, including human antibodies, humanized antibodies, multispecific and/or multivalent antibodies, antibody production, and clinical uses of antibodies.

Technology

Our clients are discovering the latest technological advances that are changing the way we live, and McCarter's patent team is active in all facets of these high tech sectors. Our

technical knowledge spans the foundational engineering disciplines. We have more than 40 engineers providing the essential experience needed for effective and efficient IP prosecution and counseling services.

We regularly work with client patent committees, management, R&D and product development groups, laboratory teams, researchers, engineers, and scientists to determine appropriate patentable subject matter and to devise strategies for maximizing patent protection in the United States and internationally. In addition McCarter's attorneys have comprehensive experience relating to freedom-to-operate studies, inventorship/ownership analyses and disputes, trade secrets issues, and proceedings before the Patent Trial and Appeal Board.

We have the legal and technical acumen to assist clients in numerous high-tech fields, such as biomedical technology, ceramics, drug delivery, nanotechnology, optoelectronics, optics, robotics, medical devices, telecommunications, advanced control systems, "green" technologies, biometrics, automotive technologies, software, distributed systems, networking, expert systems, microprocessor architectures, electronic circuitry, 3D display technologies, and a range of defense, aerospace, and energy technologies.

For the technology companies and research universities we represent, we have prosecuted patent applications in the areas of advanced control systems, telecommunications, color measurement, plasma physics devices, bio materials, bio fuel, fuel and solar cells, copper and fiber optic communication, medical devices and implants, surgical tools, laser devices, microprocessors, 3D visuals, nanotechnology-based products/systems, semiconductor, and computer hardware and software.

Alerts

The Rise of AI: Inventorship Challenges and Opportunities for Natural Persons, Intellectual Property Alert, 2.22.2024

Does Not Compute: UK Supreme Court Rules That AI-Generated Inventions Cannot Receive Patents, Intellectual Property Alert, 1.8.2024

End of Line: Supreme Court Deletes AI Inventorship, Intellectual Property Alert, 4.28.2023

New Rules Will Help Patents Survive IPRs, Intellectual Property Alert, 12.9.2020

Sovereign Immunity Does Not Shield State-Owned Patents from Inter Partes Review, Patent Alert, 5.18.2019

"Oh Yes, Wait a Minute, Mr. Postman"—Supreme Court Says Post Office (and the Government) Can't Challenge Patents in Patent Office Proceedings, Patent Alert, 5.11.2019

Articles

Wallflowers: Biosimilars Don't Dance – They Go to the PTAB, IAM Life Sciences 2021, 7.1.2021

The Patent Is Dead; Long Live The Royalties!, Pharma & Medtech Business Intelligence, 5.13.2015

Tips for Trying Your 1st Patent Infringement Case, Law360, 3.13.2015

U.S. Supreme Court Sheds New Light on Patent Licensing Relationships, New Jersey Law Journal, 9.12.2014

Declaratory Judgment Actions – Reconciling the Federal Circuit’s Organic Seed Growers Opinion with the U.S. Supreme Court’s Recent Lexmark Decision, New York Intellectual Property Law Association, 5.13.2014

Speaking Engagements

Patent Law Course, Harvard Medical School, 2.6.2024

Translational Biomedical Engineering, Harvard Medical School, 2.6.2023

USPTO Stakeholder Listening Session with Director Kathi Vidal, United States Patent and Trademark Office, 5.7.2022

Translational Biomedical Engineering, Harvard Medical School, 2.11.2020

Biotech Bootcamp Weekend, Suffolk University & Ventac Partners , 7.13-15.2018

EP/US Comparative IP Law Seminar 2015 – Comparative Patent Practice Conference in Tokyo, Japan, CPPC Reception, 11.17.2015

Alice-Proofing Patent Claims and Related Issues, New Jersey Intellectual Property Law Association (NJIPLA), 11.12.2015

Patents & Trademarks & Copyrights (Oh My!): Protecting Your Startup’s Most Valuable Assets, McCarter & English Entrepreneurs Series, 10.1.2014

Comparative Patent Practice Conference in Tokyo, Japan, 11.12.2013

Patent Reform, The America Invents Act (AIA), 9.22.2011

On Antibodies...From Market Developments to Patent Protection, European Patent Attorneys, 1.30.2009

Webinars

Mentor Mantras: Exploring Careers in Patent Law, STEMPeers, 11.18.2023

Career Paths in Patent Law, University of Connecticut Fellowship Seminar Series, 5.30.2021

Quoted

Lawyers Anticipate ‘Heightened Obligation’ to Probe Clients over AI Use, Managing IP, 2.14.2024

How to License a Light Bulb Moment: A Patent Lawyer Q&A, ChristianaCare Gene Editing Institute, 1.24.2024

FDA Approves First Crispr Gene Therapy, Affordability Questions Remain, Inside Health Policy , 12.8.2023

First-Ever CRISPR Drug, Made by Two Boston Companies, Is Approved in the US, Boston Business Journal, 12.8.2023

The Rapid Rise of Generative AI Threatens to Upend US Patent System, Financial Times, 4.26.2023

Russian IP Animus Fuels Risk, Uncertainty as Firms Recalibrate, Bloomberg Law, 3.21.2022

Celebrating (?) the America Invents Act: Ten Years On, Many IP Stakeholders Say it’s Time for a Second Look, IPWatchdog, 9.16.2021

No Easy Arthrex Fix as Full-Court Review Looms, Attorneys Say, Bloomberg Law , 12.3.2019

Fed. Circ. Ruling Shows Limits of USPTO Eligibility Guidance, Law360, 4.3.2019

Patent Lawsuits Dropped Off Sharply in Mass. Courts Last Year, Boston Business Journal, 1.11.2019

AIA Case at High Court May Be about More Than Patents, Law360, 10.30.2018

Broad Institute Wins Landmark Case over Gene Editing Patents, Boston Business Journal, 9.10.2018

Change to Local Rules May Bring More Patent Cases to Mass., Law360, 1.11.2018

4 Reasons Boston Can Be A Great Place For Patent Cases, Law360, 9.20.2017

4 Ways to Stay on a Judge's Good Side during a Patent Case, Law360, 5.15.2017

Justices' Enhanced Damages Ruling Gives Patents More Teeth, Law360, 5.13.2016

5 Ways To Botch A Patent Trial, Law360, 5.27.2016

USPTO Patent Guidelines Give Hope To Life Sciences Cos., Law360, 5.6.2016

Patent Lawsuits On The Upswing Again In Massachusetts, Boston Business Journal, 3.24.2016

Report: Patent Litigation Bounced Back, Migrated to Texas in 2015, Bloomberg Big Law Business, 3.15.2016

Is Filing a Patent Worthwhile?, The Herald-Tribune, 1.10.2016

5 Ways IP Attys Can Make The World Better This Year, Law360, 1.4.2016

Erik Belt comments on BPLA quoted in "Law & Money" section of Boston Business Journal, Boston Business Journal, 12.18.2015

Forget Patent Trolls. This Boston Attorney Is Battling Silicon Valley's Darth Vader, Boston Business Journal, 12.10.2015

BU Wins \$13 Million in Patent Infringement Suit, BU Today, 12.7.2015

Fed. Circ. Fortifies PTAB Against Constitutional Attacks, Law360, 12.2.2015

PTAB's Joinder Ruling Gives Petitioners Extra Flexibility, Law360, 10.13.2015

Attorneys React to Supreme Court Patent Royalties Case, Law360, 5.22.2015

Justices' Expired-Patent Royalties Ban to Spur Clever Deals, Law360, 5.22.2015

Attorney: Supreme Court's Spider-Man Ruling Could Help Biotech, Tech Deals, Boston Business Journal, 5.22.2015

Despite Drop in New Patent Suits, Attys Hard at Work, Law360, 2.27.2015

High Court Claim Construction Ruling Set to Spur New Fights, Law360, 1.20.2015

5 Tips For Getting Software Patents Approved Post-Alice, Law360, 9.2.2014

Patent Cases to Watch in the 2nd Half of 2014, Law360, 7.28.2014

Lawyers Weigh In on High Court's Software Patent Ruling, Law360, 5.19.2014

Attorneys React To High Court's Gene Patent Ruling, Law360, 5.14.2014

5 Tips For Killing Patents In AIA Reviews, Law360, 4.17.2014